A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug

T. L. Leunbach*, A. T. Hansen, M. Madsen, R. Cipliene, P. S. Christensen, A. J. Schou

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

7 Citationer (Scopus)
33 Downloads (Pure)

Abstract

We report a boy with hypercalcemia due to neonatal severe hyperparathyroidism (NSHPT) caused by a compound heterozygous mutation in the calcium sensing receptor (CaSR) managed successfully on a type II calcimimetic drug. The hypercalcemia was temporarily treated by hyperhydration, bisphosphonate and calcium depleted milk. At 29 days of age cinacalcet was introduced. The starting dose was 0.5 mg/kg/day and was subsequently titrated to the point of efficacy (5.2 mg/kg/day) when a persuasive reduction in parathyroid hormone and calcium concentrations was observed. We propose a trial of type II calcimimetics in newborns with NSHPT irrespective of the genetic mutation and advocate that residual functionality of the CaSR predict the drug efficacy.

OriginalsprogEngelsk
Artikelnummer100761
TidsskriftBone Reports
Vol/bind14
Antal sider5
ISSN2352-1872
DOI
StatusUdgivet - jun. 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'A novel case of neonatal severe hyperparathyroidism successfully treated with a type II calcimimetic drug'. Sammen danner de et unikt fingeraftryk.

Citationsformater